, Volume 201, Issue 4, pp 541–548 | Cite as

Fourteen well-described caffeine withdrawal symptoms factor into three clusters

  • Stephen Ozsungur
  • Darren Brenner
  • Ahmed El-SohemyEmail author
Original Investigation



Abrupt cessation of caffeine often results in several withdrawal symptoms among habitual caffeine consumers.


The objective of the study was to determine whether caffeine withdrawal symptoms co-exist as clusters in some individuals.

Materials and methods

Withdrawal symptoms and caffeine intake were assessed for men (n = 126) and women (n = 369), aged 20–29, using a caffeine habits questionnaire and a semi-quantitative food frequency questionnaire, respectively. Principal components factor analysis was used to identify common underlying factors among 14 well-described caffeine withdrawal symptoms. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to determine if the likelihood of reporting a withdrawal factor was associated with habitual caffeine consumption.


The 14 withdrawal symptoms were grouped into three factors termed “fatigue and headache”, “dysphoric mood”, and “flu-like somatic”. The likelihood of reporting the fatigue and headache and dysphoric mood factors increased with higher levels of habitual caffeine consumption. Compared to <100 mg/day of caffeine, the ORs (95% CI) of reporting the fatigue and headache factor with a habitual intake of 100–200 mg/day and >200 mg/day were 1.97 (1.21, 3.21) and 4.44 (2.50, 7.86), respectively. The corresponding ORs (95% CI) for the dysphoric mood factor were 1.55 (0.96, 2.52) and 3.34 (1.99, 5.60).


The 14 well-described caffeine withdrawal symptoms factor into three clusters, suggesting the existence of three distinct underlying mechanisms of caffeine withdrawal. Increasing habitual caffeine consumption is associated with an increased likelihood of reporting the fatigue and headache and dysphoric mood symptoms, but not the flu-like somatic symptoms.


Caffeine Cessation Withdrawal Dependence Fatigue Mood Dysphoria DSM ICD Human 



This work was supported by the Advanced Foods and Materials Network (AFMNet). A. El-Sohemy holds a Canada Research Chair in Nutrigenomics.

Disclosure/conflict of interest

The authors report no conflicts of interest.


  1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th edn. American Psychiatric Association, USAGoogle Scholar
  2. Barone JJ, Roberts HR (1996) Caffeine consumption. Food Chem Toxicol 34:119–129PubMedCrossRefGoogle Scholar
  3. Cornelis MC, El-Sohemy A (2007) Coffee, caffeine, and coronary heart disease. Curr Opin Lipidol 18:13–19PubMedCrossRefGoogle Scholar
  4. Dews PB, Curtis GL, Hanford KJ, O’Brien CP (1999) The frequency of caffeine withdrawal in a population-based survey and in a controlled, blinded pilot experiment. J Clin Pharmacol 39:1221–1232PubMedCrossRefGoogle Scholar
  5. Evans SM, Griffiths RR (1999) Caffeine withdrawal: a parametric analysis of caffeine dosing conditions. J Pharmacol Exp Ther 289:285–294PubMedGoogle Scholar
  6. Evans SM, Critchfield TS, Griffiths RR (1994) Caffeine reinforcement demonstrated in a majority of moderate caffeine users. Behav Pharmacol 5:231–238PubMedCrossRefGoogle Scholar
  7. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83–133PubMedGoogle Scholar
  8. Goldstein A (1964) Wakefulness caused by caffeine. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 248:269–278PubMedGoogle Scholar
  9. Goldstein A, Kaizer S (1969) Psychotropic effects of caffeine in man. 3. A questionnaire survey of coffee drinking and its effects in a group of housewives. Clin Pharmacol Ther 10:477–488PubMedGoogle Scholar
  10. Griffiths RR, Mumford GK (1996) Caffeine reinforcement, discrimination, tolerance and physical dependence in laboratory animals and humans. In: Balster RL, Kuhar MJ, Schuster CR (eds) Pharmacological aspects of drug dependence: toward an integrated neurobehavioral approach (Handbook of experimental pharmacology, v. 118). Springer, BerlinGoogle Scholar
  11. Griffiths RR, Woodson PP (1988) Caffeine physical dependence: a review of human and laboratory animal studies. Psychopharmacology (Berl) 94:437–451CrossRefGoogle Scholar
  12. Griffiths RR, Bigelow GE, Liebson IA (1986) Human coffee drinking: reinforcing and physical dependence producing effects of caffeine. J Pharmacol Exp Ther 239:416–425PubMedGoogle Scholar
  13. Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B, Woodson PP (1990) Low-dose caffeine physical dependence in humans. J Pharmacol Exp Ther 255:1123–1132PubMedGoogle Scholar
  14. Hofer I, Battig K (1994) Cardiovascular, behavioral, and subjective effects of caffeine under field conditions. Pharmacol Biochem Behav 48:899–908PubMedCrossRefGoogle Scholar
  15. Hughes JR, Oliveto AH (1997) A systematic survey of caffeine intake in Vermont. Exp Clin Psychopharmacol 5:393–398PubMedCrossRefGoogle Scholar
  16. Hughes JR, Higgins ST, Bickel WK, Hunt WK, Fenwick JW, Gulliver SB, Mireault GC (1991) Caffeine self-administration, withdrawal, and adverse effects among coffee drinkers. Arch Gen Psychiatry 48:611–617PubMedGoogle Scholar
  17. Hughes JR, Oliveto AH, Bickel WK, Higgins ST, Badger GJ (1993) Caffeine self-administration and withdrawal: incidence, individual differences and interrelationships. Drug Alcohol Depend 32:239–246PubMedCrossRefGoogle Scholar
  18. Hughes JR, Oliveto AH, Liguori A, Carpenter J, Howard T (1998) Endorsement of DSM-IV dependence criteria among caffeine users. Drug Alcohol Depend 52:99–107PubMedCrossRefGoogle Scholar
  19. Jones HE, Herning RI, Cadet JL, Griffiths RR (2000) Caffeine withdrawal increases cerebral blood flow velocity and alters quantitative electroencephalography (EEG) activity. Psychopharmacology (Berl) 147:371–377CrossRefGoogle Scholar
  20. Juliano LM, Griffiths RR (2004) A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology 176:1–29PubMedCrossRefGoogle Scholar
  21. Kabagambe EK, Baylin A, Allan DA, Siles X, Spiegelman D, Campos H (2001) Application of the method of triads to evaluate the performance of food frequency questionnaires and biomarkers as indicators of long-term dietary intake. Am J Epidemiol 154:1126–1135PubMedCrossRefGoogle Scholar
  22. Kaiser HF (1958) The varimax criterion for analytic rotation in factor analysis. Psychometrika 23:187–200CrossRefGoogle Scholar
  23. Kim J-o, Mueller CW (1978) Factor analysis: statistical methods and practical issues. Sage Publications, CaliforniaGoogle Scholar
  24. Lader M, Cardwell C, Shine P, Scott N (1996) Caffeine withdrawal symptoms and rate of metabolism. J Psychopharmacol 10:110–118CrossRefGoogle Scholar
  25. Lane JD (1997) Effects of brief caffeinated-beverage deprivation on mood, symptoms, and psychomotor performance. Pharmacol Biochem Behav 58:203–208PubMedCrossRefGoogle Scholar
  26. Lane JD, Phillips-Bute BG (1998) Caffeine deprivation affects vigilance performance and mood. Physiol Behav 65:171–175PubMedCrossRefGoogle Scholar
  27. Rogers PJ (2007) Caffeine, mood and mental performance in everyday life. British Nutrition Foundation 32:84–89Google Scholar
  28. Roller L (1981) Caffeinism: subjective quantitative aspect of withdrawal syndrome. Med J Aust 1:146PubMedGoogle Scholar
  29. Satel S (2006) Is caffeine addictive?—a review of the literature. Am J Drug Alcohol Abuse 32:493–502PubMedCrossRefGoogle Scholar
  30. Silverman K, Evans SM, Strain EC, Griffiths RR (1992) Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 327:1109–1114PubMedGoogle Scholar
  31. Strain EC, Mumford GK, Silverman K, Griffiths RR (1994) Caffeine dependence syndrome. Evidence from case histories and experimental evaluations. Jama 272:1043–1048PubMedCrossRefGoogle Scholar
  32. USDA (2007) National Nutrient Database for Standard ReferenceGoogle Scholar
  33. Verhoeff FH, Millar JM (1990) Does caffeine contribute to postoperative morbidity. Lancet 336:632PubMedCrossRefGoogle Scholar
  34. World Health Organization (1992a) ICD-10: international statistical classification of diseases and related health problems, 10th revision. edn. World Health Organization, GenevaGoogle Scholar
  35. World Health Organization (1992b) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, GenevaGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Stephen Ozsungur
    • 1
  • Darren Brenner
    • 1
  • Ahmed El-Sohemy
    • 1
    Email author
  1. 1.Department of Nutritional Sciences, Room 350University of TorontoTorontoCanada

Personalised recommendations